Masa Suekane

Masa Suekane is a Partner at Bain Capital, based in Tokyo, where he leads much of the firm's Japan private equity activity across the Healthcare, Industrials, and Financial Services verticals. He joined Bain Capital in 2006 and is a founding member of the firm's Tokyo office, making him one of the longest-tenured leaders of Bain Capital's private equity franchise in Japan. He sits on the Asia-Pacific Private Equity team and has been a member of the Asia private equity investment committee.

Before joining Bain Capital, Suekane was a consultant at The Boston Consulting Group, where he advised clients across the industrial-goods, financial, high-tech, and consumer-products industries. He earned an MBA from Harvard Business School and a BS from the University of Tokyo.

Over nearly two decades at Bain Capital he has been associated with many of the firm's landmark Japanese transactions — spanning industrial carve-outs, healthcare, and technology — and has become one of the firm's public voices on Japan strategy, giving interviews to outlets such as Mergermarket/ION Analytics and the Asian Venture Capital Journal (AVCJ). His stated long-horizon philosophy is characteristic of the firm's Japan posture: *"We have our business in Japan from twenty years ago and have the will to continue it for another 50 to 100 years."*

> Note on the stub data: The provided stub labeled Masa Suekane as an "Angel Investor" writing "Seed Round" checks. Public sources do not support this. He is a control-oriented private equity Partner at Bain Capital doing large buyouts and carve-outs; the profile above reflects the verified reality rather than the stub classification.

• Control buyouts of Japanese companies, not early-stage/angel bets — focused on carve-outs, divestitures, and take-privates rather than minority venture rounds.
• Corporate carve-outs are a core theme: in a 2025 conversation with AVCJ, Suekane (with colleague Naofumi Nishi) highlighted the growing momentum behind corporate carve-outs and divestments in Japan (e.g., York Holdings from Seven & I).
• Life sciences / pharma edge: Bain Capital deploys a Boston-based team of ~30 physicians and biopharma specialists to evaluate pre-approval drug candidates — allowing it to pursue core pharmaceuticals and drug-discovery assets rather than only revenue-generating pharma companies (per Jan 2025 Mergermarket interview).
• Real estate on the balance sheet: targeting Japanese companies that hold substantial (often underutilized) real estate, which he notes is proportionally larger in Japan than in the US.
• Long-term, relationship-driven approach: generally avoids unsolicited/hostile offers as a matter of practice (framing the Fuji Soft situation as an exception driven by board-process concerns).
• Sectors: Healthcare/life sciences, Industrials, Financial Services, Energy, and Technology, with a Japan-first geographic lens.